An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Wilmington Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV ODT (metoclopramide HCl), an orally disintegrating formulation of metoclopramide for the treatment of gastroesophageal reflux disease (GERD) and diabetic gastroparesis.
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
Sequoia Hospital announced that the Cardiac Arrhythmia Program has completed 1,000 atrial fibrillation (A-Fib) ablation procedures, making it the highest total volume A-Fib ablation institution currently performing ablations in Northern and Central California.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
Electrophysiologists Robert Stevenson, MD, and Jeffrey L. Williams, MD, MS, FACC, are safely implanting cardiac resynchronization therapy defibrillators in the Good Samaritan Hospital (GSH) Cardiology (Heart Failure) Program.
eCardio announced today their inclusion on the Inc. magazine's annual list of America's fastest-growing private companies - the Inc. 500. Inc. magazine released the list on Wednesday, August 12. eCardio was included in the top quarter as #117 with a three-year sales growth of 1,424%.
Mellanie True Hills knows personally the toll that atrial fibrillation (afib) takes. Just two years ago, with a sense of urgency about afib that only a survivor can possess, she designated September as Atrial Fibrillation Month.
Atrial fibrillation ablation is one of the fastest growing techniques in cardiology and due to the very high number of patients that might be candidates to this procedure, a significant number of resources will have to be devoted to it to be able to treat them in the following years.
Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company’s Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).
Cholesterol can affect the flow of the electrical currents that generate the heart beat, according to a study from two UBC cardiovascular researchers funded by the Heart and Stroke Foundation of BC & Yukon. The research team has just published the important discovery about the causes of cardiac arrhythmias (abnormal heartbeats) in one of the world's leading scientific journals.
Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.
Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.
For those who suffer from fainting spells, the mysterious episodes can be quite scary. Far too often, fainting is chalked up to stress or other mental health issues. However, medical experts at Rush University Medical Center say that reoccurring fainting spells, also known as syncope, could be an important symptom that can point to a more serious, underlying cardiovascular condition.
Researchers may be able to predict future severe cardiac events in patients with known, stable coronary artery disease (CAD) using coronary calcium scoring, according to a study published in the online edition of Radiology.
The latest statistics regarding the use of pacemakers and implantable cardiac devices in Europe was presented on Sunday 21 June, at EUROPACE 2009, the meeting of the European Heart Rhythm Association (EHRA) which takes place in Berlin, Germany from 21 to 24 June.
Angiotensin 1-7, a hormone in the body that has cardiovascular benefits, improves the metabolic syndrome in rats, according to a new study. The results were presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C.
University at Buffalo researchers have demonstrated for the first time that injecting adult bone marrow stem cells into skeletal muscle can repair cardiac tissue, reversing heart failure.
Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, a major international study has found.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.